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Abstract
Celastramycin A, a small molecule that inhibits the production of antibacterial peptides in an ex vivo culture system of
Drosophila, suppresses the TNFa-mediated induction of IL-8 in mammalian cells. To understand its molecular mechanism,
we examined Celastramycin A binding proteins and investigated their biological functions. Our screening and subsequent
pull-down assay revealed ZFC3H1 (also known as CCDC131 or CSRC2), an uncharacterized zinc finger protein, as a
Celastramycin A binding protein. The knockdown of ZFC3H1 reduced IL-8 expression levels in the TNFa-stimulated lung
carcinoma cell line, LU99, and UV-irradiated HeLa cells. Based on reporter assay results, we concluded that ZFC3H1
participates in the transcriptional activation of IL-8. The findings of our UV-irradiation experiments implied that ZFC3H1 may
indirectly interact with ERCC1 in an activated DNA repair complex. Thus, we designated ZFC3H1 as a mammalian target of
Celastramycin A (mTOC).
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Introduction
Many attempts have been made to identify new reagents that
may control innate immune reactions [1–4]. Although the innate
immune system protects the host from continual attacks by
pathogens, inflammatory responses may lead to unwanted conse-
quences, such as rheumatoid arthritis [5,6], diabetes [7,8], or tumor
metastasis [9–12], in some cases. Recent studies designated such an
imbalance of inflammatory reactions as ‘‘homeostatic inflamma-
tion’’, and suggested that the containment of inflammatory
cytokines by neutralizing antibodies may prevent the formation of
the pre-metastatic phase in the tumor metastasis process [13].
Celastramycin A, a benzoyl pyrrole-type compound (Figure 1A)
originally found in a bacteria extract, arose from functional
screenings using an ex vivo culture system of Drosophila [14,15].
This compound may modulate host intracellular signaling by
inhibiting the production of antibacterial peptides. Thus, its
potential applications are expected to be in the inhibition of
proinflammatory reactions in cells. Celastramycin A has been
shown to reduce TNFa-induced IL-8 production in a mammalian
cell culture assay using human umbilical vascular endothelial cells.
A previous study reported that the transcription factor Relish was
considered to be a likely target molecule of Celastramycin A in
Drosophila cells; hence, NF-kB-related signal transduction mole-
cules may be a target molecule in mammalian cells. However,
detailed information on actual Celastramycin A binding mole-
cule(s) and its molecular mechanisms has not yet been obtained. In
this study, we identified the zinc finger protein, ZFC3H1, as a
Celastramycin A binding protein, and determined that ZFC3H1
plays an important role in the expression of inflammatory
cytokines. To the best of our knowledge, this is the first study to
investigate the biological functions of ZFC3H1. The transcrip-
tional activity responsible for the expression of IL-8 was markedly
reduced in the absence of ZFC3H1.
Materials and Methods
Cells and antibodies
HeLa cells that stably expressed scrambled shRNA, shERCC1,
shXPA, or shXPC were kindly gifted from Dr. Denis Biard. LU99
cells were obtained from the RIKEN Bioresource Center (Tokyo,
JAPAN) and maintained in RPMI1640 supplemented with 10%
FBS. The ZFC3H1 (HPA007151) antibody was obtained from
Sigma-Aldrich (St. Louis MO, USA). Phospho-p65 (Cat.
No. 3033), IkBa (Cat. No. 4812), p38 (Cat. No. 9212), phospho-
p38 (Cat. No. 9211), JNK (Cat No. 9252), phospho-JNK (Cat.
No. 9251), ERK (Cat. No. 9102), phospho-ERK (Cat. No. 9101),
and phospho-IkBa (Cat. No. 2859) antibodies were from Cell
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Figure 1. Determination of a Celastramycin A binding protein. (A) Structure of Celastramycin A (R =H) and its derivatives. The NH2 derivative
was immobilized in magnetic beads for the pull-down assay and the biotin adduct was used for protoarray hybridization. (B) Relative IL-8 and CCL2
expression levels in LU99 cells determined by quantitative PCR. RNAs were isolated 90 min after the TNFa (10 ng/ml) stimulation in the absence or
presence of Celastramycin A (0.1 mg/ml). Data were normalized to b-actin and control LU99 data was set as 1. Three independent experiments. (C)
Celastramycin A pull-down assay. Halo-tagged ZFC3H1 or unrelated proteins with similar molecular weights (150 kDa–250 kDa) overexpressed in
HEK293T cells. Input western blot data (upper panel) shows the presence of the Halo-tagged protein (anti-Halo-tag probing). The lower panel shows
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Signaling Technology (Danvers MA, USA). The P65 (sc-109),
ERCC1 (sc-17809), lamin A/C (sc-20681) and RNA polymerase II
(Pol II, sc-55492) antibodies were from Santa Cruz Biotechnology.
Nuclear extract preparation
Cells were suspended in HEPES buffer (10 mM HEPES,
pH 7.6, 15 mM KCl, 2 mM MgCl2, 0.1 mM EDTA, 1 mM
dithiothreitol) with protease inhibitors. After brief centrifugation
(1,0006g, 5 min), the cell pellet was suspended in HEPES buffer
with 0.2% IGEPAL. The sample was centrifuged (1,0006 g,
5 min) to separate the cytosolic fraction and nuclei, and the
nuclear pellet was washed with HEPES-sucrose buffer (10 mM
HEPES, pH 7.6, 250 mM sucrose, 15 mM KCl, 2 mM MgCl2,
0.5 M EDTA, 1 mM dithiothreitol).
Electrophoresis Mobility Shift Assay (EMSA)
Synthetic oligonucleotides (AP-1 probe; 59-GGAAGTGTGAT-
GACTCAGGTTTGCCCTG-39, and NF-kB probe; 59-CAAAT-
CGTGGAATTTCCTCTGACATAATGAAAAG-39) were la-
beled with biotin (Biotin 39 End DNA Labeling Kit, Thermo).
Nuclear extracts were mixed with poly dI-dC (0.1 mg/ml), 1 mM
dithiothreitol, and biotin labeled oligonucleotide with or without
non-labeled competitor. The following shows mutant competitor
sequences; mutant AP-1 59- GGAAGTGTGATATCTGTGGT-
TTGCCCTG-39, and mutant NF-kB 59-CAAATCGTGGAAT-
TTAAACTGACATAATGAAAAG-39. The underlined nucleo-
tides display mutations. Samples were electrophoresed on a 5%
polyacrylamide gel using 0.56TBE buffer. After the electropho-
resis, samples were electrotransferred onto a nylon membrane for
30 min using 0.56TBE buffer. The transferred nucleotides were
fixed with UV irradiation (120 mJ/cm2) and biotin-labeled
nucleotides were detected by using streptavidin-HRP system
(LightShift Chemiluminescent EMSA Kit, Thermo).
Chromatin Immunoprecipitation (ChIP) assay
We used ChIP-IT Express (Active Motif, Carlsbad, CA) to
perform ChIP assays. Briefly, chromatin complexes isolated from
cells fixed with 1% formaldehyde were sonicated (Bioruptor UCD-
250, Cosmobio, Tokyo, Japan) and immunoprecipitated by
control IgG or RNA polymerase II antibody. The IL-8 promoter
region contained in the immunoprecipitated samples were
quantitated on a real-time PCR machine. The primers and probe
set for IL-8 promoter region was as follows; Forward primer, 59-
CATCAGTTGCAAATCGTGGA-39, Reverse primer, 59-AGA-
ACTTATGCACCCTCATCTTTT-39, probe, Roche Universal
ProbeLibrary Probe #6 (Roche applied Science).
Plasmid and siRNA
A Halo-tagged ZFC3H1 expression construct (FHC00095) was
purchased from Promega (Madison WI, USA). Negative control
siRNA (Cat. No. 4390843) and ZFC3H1 siRNA (Cat.
No. 4392420) were obtained from Life Technologies (Carlsbad
CA, USA). Regarding transfections, plasmid and/or siRNA were
mixed with RNAiMAX (Life Technologies) or Hilymax (Dojindo,
Kumamoto JAPAN) prior to being applied to cells.
Celastramycin A and its derivatives
Celastramycin A was synthesized as previously reported [15].
Celastramycin A-NH2 and biotinylated Celastramycin A (Fig-
ure 1A) were synthesized in a similar manner to that of
Celastramycin A. The details of the synthetic methods for these
derivatives are described elsewhere. To make a stock solution,
Celastramycin A was dissolved in DMSO to give a final
concentration of 20 mg/ml, and the stock solution was then
diluted in PBS prior to use.
Protein microarray
A protoarray, a human protein microarray (PAH0525011), was
purchased from Life Technologies. This was probed with
biotinylated Celastramycin A followed by hybridization with a
streptavidin-Alexa Fluor 647 conjugate. Fluorescence was scanned
with GenePix 4100A (PerkinElmer, Boston MA USA).
Pull-down assay
Celastramycin A-NH2, dissolved in 1.25 M borate buffer,
pH 9.5, 1% Triton X-100, was mixed with 5 mg of Dynabeads M-
280 Tosylactivated (Life Technologies) at 37uC overnight. After
washing, the magnetic beads were suspended in PBS with 0.1%
BSA. A small aliquot of magnetic beads (0.2 mg) was mixed with
the HEK293T cell lysate overexpressing the halo-tagged protein.
Beads were washed with PBS-0.1% Tween20 and mixed with SDS
sample loading buffer containing b-mercaptoethanol. Samples
were then electrophoresed on a 5–20% gradient gel, and
electrotransferred to a polyvinylidene difluoride membrane. The
membrane was blocked with blocking buffer (Nacalai Tesque,
Kyoto, Japan) and probed with the anti-halo-tag (Promega) and
anti-Rabbit IgG-HRP conjugate (GE Healthcare). Finally, protein
bands were detected using a chemiluminescence reagent (Im-
munostar LD, WAKO Pure Chemicals) and a CCD camera
system (ImageQuant LAS 4000mini, GE Healthcare).
Quantitative–PCR (qPCR)
Total RNA was extracted using Trizol reagent (Life Technol-
ogies). Complementary DNA was synthesized with Primescript
(Takara, Tokyo, Japan) reverse transcriptase with a random
primer (Takara). Quantitative PCR analysis was performed using
the SYBR Green master mixture (Applied Biosystems, Carlsbad
CA, USA) and StepOneplus real time PCR system (Applied
Biosystems). The following primer sets were used; b-actin, 59-
GCACAGAGCCTCGCCTT-39 and 59-GTTGTCGACGACG-
AGCG-39; IL-8, 59-AGCACTCCTTGGCAAAACTG-39 and 59-
CAAGAGCCAGGAAGAAACCA-39; CCL2, 59-GCCTCCAG-
CATGAAAGTCTC-39 and 59-AGGTGACTGGGGCATTGA-
T-39.
Enzyme-Linked ImmunoSorbent Assay (ELISA)
IL-8 and IL-6 concentrations in the culture media were
quantitated by a Quantikine ELISA system (R&D Systems,
Minneapolis MN, USA).
the Halo-tag probing western blot after Celastramycin A-immobilized bead pull-down. (D) IL-8 expression ratio in TNFa-stimulated LU99 cells. LU99
cells were transfected with control siRNA or ZFC3H1 siRNA. RNAs were isolated 90 min after the TNFa (10 ng/ml) stimulation in the absence or
presence of Celastramycin A (0.1 mg/ml). Relative IL-8 expression ratios were calculated based on the formula to show the activity of Celastramycin A.
Three independent experiments. (E) Quantitation of IL-8 in the LU99 culture media. IL-8 levels in the LU99 cell culture media were determined by
ELISA. LU99 cells were transfected with control siRNA or ZFC3H1 siRNA, and culture media were harvested 6 h after the TNFa (10 ng/ml) stimulation.
Celastramycin A (0.1 mg/ml) reduced IL-8 concentrations in control siRNA-transfected LU99 cells, while the effect was decreased in ZFC3H1 siRNA-
transfected LU99 cells. Three independent experiments. *P,0.05. NS, not significant.
doi:10.1371/journal.pone.0108957.g001
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Reporter assay
PCR was performed using human genomic DNA with a primer
set (59- GGTACCAAATTGTGGAGCTTCAGT-39 and 59- CT-
CGAGTCTCTGAAAGTTTGTGCCTTATG-39). The PCR
product containing the IL-8 promoter region (2238–+29) was
cloned into the KpnI-XhoI site of a Firefly luciferase pGL4.11
vector (Promega). Mutations in the AP-1, C/EBP, and NF-kB
elements of this construct were introduced based on a previous
study [16]. All plasmids were confirmed by nucleotide sequencing.
Cells were seeded in 24-well tissue culture plates. A total of
500 ng of the pGL4.11-based reporter construct and 5 ng of
pGL4.74 as an internal control (Promega) were transfected in each
well. Cells were washed once with PBS the following day and lysed
with passive lysis buffer (Promega). Luciferase activity was assayed
using the Dual-Luciferase Reporter Assay System (Promega) and a
luminometer (GLOMAX 96 microplate reader, Promega).
Immunofluorescence Microscopy
HeLa cells were fixed with 3.7% formaldehyde and permeabi-
lized for 10 min at room temperature in PBS-0.1% Triton X-100
for 5 min. Cells were then incubated with PBS-2% BSA for
15 min, and with primary antibodies and 49-6 diamidino-2-
phenylindole (DAPI)-containing buffer. After washing with PBS,
secondary antibodies with fluorescent dye (Alexa Fluor 488, Alexa
Fluor 546, or Alexa Fluor 647) were applied. Images were
obtained using a confocal laser scanning microscope (LSM710,
Carl Zeiss) and processed by ZEN 2011 Image software.
Statistical analysis
All data were expressed as the mean 6 standard deviation and
analyzed using the Student’s t-test. P values less than 0.05 were
considered significant (*). NS=not significant.
Results
The expression of proinflammatory cytokines was markedly and
rapidly increased by the TNFa stimulation. Figure 1B shows the
relative IL-8 expression levels determined by qPCR analysis of the
LU99 cell line, which was derived from human lung carcinoma.
The expression of IL-8 was up-regulated .100-fold by the TNFa
stimulation (5 ng/ml, 90 min), but was reduced by 50% in the
presence of 0.1 mg/ml Celastramycin A. To evaluate cellular
toxicity of Celastramycin A, cell viability assay was performed.
The results shown in Figure S1 demonstrated that incubation with
1 mg/ml of Celastramycin A for 6 h reduced LU99 cell viability by
10% but no significant loss was seen in the lower Celastramycin A
concentration region (0.01–0.1 mg/ml), whereas TNFa induced
IL-8 expression was inhibited. The expression of CCL2 was also
up-regulated approximately 40-fold by the TNFa stimulation, but
was reduced by 50% following the addition of Celastramycin A.
Almost the same effect was observed in a human breast carcinoma
cell line (HCC1954 cells, data not shown).
Protein array screening was performed to identify Celastramy-
cin A binding proteins. The array, on which recombinant human
proteins were spotted, was hybridized with biotinylated Celas-
tramycin A followed by fluorescence-labeled streptavidin probing.
This assay identified several molecules as Celastramycin A binding
proteins, and a pull-down assay confirmed that the ZFC3H1
protein bound to Celastramycin A. Figure 1C shows the results of
a pull-down assay, which revealed that the N-terminal Halo-
tagged full length of ZFC3H1 was concentrated by magnetic beads
covalently binding Celastramycin A with a spacer group, while
two other unrelated proteins failed to bind the ligand.
ZFC3H1 knockdown experiments demonstrated that the
Celastramycin-dependent IL-8 reduction was canceled by
ZFC3H1 siRNA transfection prior to the TNFa stimulation
(Figure 1D). Quantification of the IL-8 protein in the culture
media clearly showed that IL-8 levels were markedly decreased in
ZFC3H1-silenced LU99 cells. Celastramycin A reduced the
production of IL-8 by 50%, but did not in ZFC3H1-silenced
LU99 cells, as shown in the graph comparing IL-8 levels between
Celastramycin A(+) control siRNA-LU99/control siRNA-LU99
and Celastramycin A(+) ZFC3H1 siRNA-LU99/ZFC3H1 siRNA-
LU99 (Figure 1E). In the IL-8 assay data, ZFC3H1 knockdown
yielded more reductions than Celastramycin A treatment. This
was attributed to the partial agonistic activity of Celastramycin A
against ZFC3H1. On the other hand, IL-6 levels were attenuated
by the addition of Celastramycin A even in the ZFC3H1-silenced
LU99 cells (Figure S2). It should be noted that ZFC3H1
knockdown was also effective to reduce IL-6 production as well
as IL-8 production (Figure S2). These data suggest that ZFC3H1
was also a key factor in regulation of IL-6 expression, but the effect
of Celastramycin A was not limited on ZFC3H1. Thus, ZFC3H1
plays an important role in TNFa signal transduction in order to
enhance the expression of downstream genes and Celastramycin A
inhibits the function of this molecule to some extent.
Western blot analysis was used to decipher the role of ZFC3H1
in intracellular TNFa signaling. ZFC3H1 was localized in the
cytosol and nucleus of LU99 cells, and no significant change was
observed in the localization pattern with the TNFa stimulation
(Figure 2A and B). The western blot data shows that ZFC3H1
siRNA transfection reduced the expression levels of ZFC3H1
protein by 80%, whereas RNA level quantifications pointed out
modest decline of ZFC3H1 (Figure 2C). In Figure 2A, the western
blots of LU99 cell total lysates with control or ZFC3H1 siRNA
transfection, IkBa was phosphorylated in control siRNA-trans-
fected LU99 cells to produce a mobility shift 5–10 min after the
TNFa stimulation, and the same response was observed in
ZFC3H1-silenced cells. No significant change was observed in the
phosphorylation of IkBa or p65 between control and ZFC3H1
siRNA-transfected LU99 cells, suggesting that ZFC3H1 was not
involved in TNFa-p65 signaling. It should be noted that minor
differences in JNK, p38, and ERK phosphorylation patterns upon
stimulation of TNFa between control and ZFC3H1 siRNA
transfected LU99 cells were observed. Thus, Celastramycin A
caused minor changes in intracellular signaling, but not enough to
explain its inhibitory effect on the production of IL-8.
The reporter assay very sensitively reflects the involvement of
transcription factors in the gene expression study. A previous study
revealed that the proximal human IL-8 promoter region
controlled IL-8 gene expression; however, other additional
elements apart from the proximal region may be able to affect
transcription [17]. In the present study, we prepared a human IL-
8 proximal region containing AP-1, C/EBP, and NF-kB binding
sites (Figure 3A), along with the mutant constructs listed in
Figure 3A [16–18]. This region, cloned into the Firefly luciferase
vector and transfected into LU99 cells, became a scaffold of
transcription factors activated by the TNFa stimulation. The
addition of Celastramycin A reduced Firefly luciferase activity,
implying that Celastramycin A kept transcription factors from
binding to the proximal IL-8 promoter region (Figure 3B). Our
experiments to determine the relative luciferase activity revealed
that the difference between control and ZFC3H1 siRNA
transfected LU99 cells was statistically significant but not between
with and without Celastramycin A (Figure 3B). The latter analyses
gave p-values 0.05–0.06. Celastramycin A slightly increased
transcription activities, which was presented in the difference
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between si-control-TNFa(2) or si-ZFC3H1-TNFa(+) with and
without Celastramycin A in Figure 3B. This increase was
attributed to the modest effect in the reporter assay. The TNFa-
mediated up-regulation of Firefly luciferase activity was observed
in ZFC3H1 siRNA-transfected LU99 cells, but this was 50% less
than that in control siRNA-transfected LU99 cells (Figure 3B).
This accounts for the fact that IL-8 transcription was reduced by
ZFC3H1 knockdown.
Site-directed mutations were introduced in the IL-8 proximal
promoter construct in attempt to narrow down the function of
ZFC3H1 in IL-8 transcription. Firefly luciferase constructs with
AP-1 site mutations (IL-8-AP-1mu), C/EBP site mutations (IL-8-
C/EBPmu), or NF-kB site mutations (IL-8-NF-kBmu) [17] were
transfected into LU99 cells, with control or ZFC3H1 siRNA. The
assay results in Figure 3C show that IL-8 transcription was
regulated by AP-1 and NF-kB in LU99 cells. Since the AP-1 or
NF-kB mutation inhibited Firefly luciferase activity, this result
indicates that these transcription factors could work synergistically.
ZFC3H1 knockdown reduced Firefly luciferase activity while
maintaining Renilla luciferase activity, which indicated that
ZFC3H1 silencing had an effect on the IL-8 promoter, but not
on the thymidine kinase promoter cloned into the pGL4.74
reference vector. This result suggests that ZFC3H1 plays an
important role in the AP-1-NF-kB transcription complex.
To investigate recruitment of basic transcription factors at the
transcription start site, ChIP assay was executed. LU99 cells with
si-control or si-ZFC3H1 were fixed with formaldehyde 0–360 min
after TNFa stimulation were harvested and sonicated nuclear
fractions were immumoprecipitated with RNA polymerase II (Pol
II) antibody. The IL-8 promoter region contained in the
immunoprecipitated samples were quantitated by using our real-
time PCR system and the results were summarized in Figure 4A.
In both control and ZFC3H1 siRNA transfected LU99 cells-ChIP
assays, Pol II yielded higher copy numbers of IL-8 promoter
Figure 2. Western blotting analysis of ZFC3H1 and intracellular signaling. (A) Control and ZFC3H1 siRNA-transfected LU99 whole cell
lysates were prepared 0–360 min after TNFa (5 ng/ml) stimulation. The panels show ZFC3H1, phosphor-p65, p65, phosphor-IkBa, IkBa, phospho-JNK,
JNK, phosphor-ERK, ERK, phosphor-p38, p38, and b-actin blots, respectively. Three independent experiments. (B) Western blot analysis of nuclear
extracts from control or ZFC3H1 siRNA-transfected LU99 cells. Cell lysates were prepared 0–360 min after the TNFa (5 ng/ml) stimulation. The panels
display ZFC3H1, phospho-p65, and lamin A/C blots, respectively. In phospho-p65 western blot, phospho-p65 specific bands were arrow-marked.
Three independent experiments. (C) Relative ZFC3H1 expression levels in LU99 cells determined by quantitative PCR. Data were normalized to b-actin.
*P,0.05.
doi:10.1371/journal.pone.0108957.g002
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region, especially 60 min after TNFa stimulation, than control
IgG. Our four independent experiments retained this tendency,
but we could not determine that the difference between Pol II
fractions of control and ZFC3H1 siRNA transfected LU99 cells-
ChIP was statistically significant. Possibly the difference were
masked by the relatively large deviation due to multiple steps in
the assay. Next, we carried out ChIP assay by using HeLa cells
because they exhibited larger differences in the TNFa induced IL-
8 expression levels between control and ZFC3H1 siRNA
transfected cells than LU99 cells. In this case a clear distinction
was observed (Figure 4B).
To analyze AP-1 and NF-kB consensus sequence binding
elements in the TNFa stimulated LU99 cells, their nuclear extracts
were tested in EMSA. Figure 4C and D show that the AP-1 probe
binding pattern appears to be constant and no critical change was
observed upon TNFa stimulation. Their AP-1 specific binding was
confirmed by assays with 200-fold excess amount of cold or AP-1
site mutant competitor oligo nucleotides listed in Figure 3A. In
contrast to AP-1 probe, NF-kB probe gave multiple bands, and in
the data a weak band appeared in a TNFa stimulation dependent
manner (Figure 4C lower panel). This band became more obscure
in another preparation as shown in Figure 4D right panels. This
figure presents the EMSA data of NF-kB probe with 200-fold
excess amount cold or NF-kB site mutant competitors described in
Figure 3A. Intensity of the NF-kB specific binding signal was so
weak that the real band can be recognized in the image with
enhanced contrast, implying that the amount of NF-kB binding
proteins in the nuclear extract was very small although NF-kB
Figure 3. Effect of ZFC3H1 on IL-8 gene transcription. (A) Structure of the human IL-8 promoter. AP-1, C/EBP, and NF-kB sites are displayed. In
the mutant constructs, underlined nucleotides were replaced. (B) IL-8(2238–+29)-pGL4.11 and the internal control vector, pGL4.74, were transfected
into LU99 cells, and their luciferase activities were measured 6 h after the TNFa (20 ng/ml) stimulation. Firefly luciferase activity was divided by Renilla
luciferase activity. Three independent experiments. (C) IL-8-pGL4.11 with or without mutations was co-transfected with pGL4.74 into LU99 cells. LU99
cells were treated with control or ZFC3H1 siRNA prior to the experiments. Cells were stimulated with TNFa (5 ng/ml) for 6 h. Firefly luciferase activity
was divided by Renilla luciferase activity. pGL4.11 is a blank vector, and this data was set as 1. Three independent experiments. *P,0.05. NS, not
significant.
doi:10.1371/journal.pone.0108957.g003
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Figure 4. Effect of ZFC3H1 on transcription and mRNA stability. (A) ChIP monitoring the TNFa-dependent occupancy of Pol II on the IL-8
promoter of si-control or si-ZFC3H1 transfected LU99 cell. Control IgG data are also shown. Values are expressed as percent input. Four independent
experiments. (B) ChIP monitoring the TNFa-dependent occupancy of Pol II on the IL-8 promoter of control or ZFC3H1 siRNA transfected HeLa cell.
Values are expressed as percent input. Three independent experiments. (C) EMSAs were carried out using nuclear extract from control or ZFC3H1
siRNA transfected LU99 cells. AP-1 probe (upper panel) and NF-kB probe (lower panel) data are presented. In EMSA with NF-kB probe, an arrow-
marked band changed its intensity upon TNFa stimulation. (D) To confirm AP-1 and NF-kB specific bindings, 200-fold excess amount of cold or
mutant competitors were added in the samples. In AP-1 probe EMSA (left panel), samples prepared 30 min after TNFa stimulation were mixed with
cold or mutant competitors. The left one lane shows sample prepared 0 min after TNFa stimulation as a reference. AP-1 specific binding remained
unchanged in the presence of mutant competitor (marked with an arrow). On the other hand, NF-kB probe EMSA (right panel), small fraction
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binding was absolutely necessary as shown in the reporter assay
(Figure 3C).
The effect of ZFC3H1 on IL-8 mRNA stability was also
examined. Figure 4E presents relative expression levels of IL-8 in
LU99 cells. Cells were incubated with 5 ng/ml of TNFa for 1 h,
and then medium was switched to 5 mg/ml actinomycin D
containing medium to take 2 h incubation. Actinomycin D
treatment allowed us to observe stability of mRNA by blocking
mRNA synthesis [19]. Two hours after the actinomycin D
treatment, amount of IL-8 mRNA in control siRNA transfected
LU99 cells, became 50% of initial value (Figure 4E, left two
columns). On the other hand, in ZFC3H1 siRNA transfected
LU99 cells the actinomycin D treatment reduced amount of IL-8
mRNA by 68% (Figure 4E, right two columns). This is interpreted
that IL-8 mRNA had short life time in the absence of ZFC3H1.
These results suggest that ZFC3H1 might be involved in
regulation of IL-8 mRNA stability. Addition of Celastramycin A
in the actinomycin D treatment step did not change the amount
IL-8 mRNA (data not shown).
IL-8 can be up-regulated by cellular stresses other than the
TNFa stimulation. UV irradiation is known to indirectly enhance
the expression of IL-8 in cells [20]. Figure 4 shows IL-8 expression
levels in HeLa cells following low level UV irradiation (20 J/m2).
IL-8 expression levels were almost the same as basal levels 1 h
remained unchanged in the presence of mutant competitor, which was clearly visualized in the enhanced contrast image (far right two lanes). The
left one lane shows sample prepared 0 min after TNFa stimulation as a reference. (E) IL-8 mRNA stability assay. LU99 cells were incubated with 5 ng/
ml TNFa for 1 h, and then medium was switched to actinomycin D (ActD, 5 mg/ml) containing medium. The ActD samples were retrieved 2 h after
the medium change. Contents of IL-8 mRNA were quantitated by using RT-qPCR method. Data were normalized to 18S rRNA and control LU99 data
was set as 1. To obtain values of TNFa (+)-ActD(2) samples as references, cells were processed immediately after the 1 h incubation with TNFa.
Numbers indicate the ratio of IL-8 mRNA remaining 2 h after the ActD treatment. Three independent experiments. *P,0.05. NS, not significant.
doi:10.1371/journal.pone.0108957.g004
Figure 5. Effect of Celastramycin A on HeLa cells. (A) IL-8 expression levels in HeLa cells transfected with control or ZFC3H1 siRNA. RNAs were
isolated from HeLa cells 5 h after UV (20 J/m2) irradiation. The concentration of Celastramycin A was 0.05 mg/ml. Data were normalized to b-actin and
control HeLa data was set as 1. Three independent experiments. (B) IL-8 expression levels in HeLa cells with control shRNA (left) and shERCC1 (right).
RNAs were isolated from HeLa cells 5 h after UV (20 J/m2) irradiation. The concentration of Celastramycin A was 0.05 mg/ml. Data were normalized to
b-actin and control HeLa (shRNA-control, left) or HeLa (shRNA-ERCC1, right) data was set as 1. Three independent experiments. (C) Confocal
microscopic images showing the localization of ZFC3H1 (green) and ERCC1 (red). Scale bar, 5 mm. *P,0.05. NS, not significant.
doi:10.1371/journal.pone.0108957.g005
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after UV irradiation, but were 10-fold higher after 5 h. No
significant changes were observed in the expression of CCL2 (data
not shown). Incubation with Celastramycin A-containing medium
following UV irradiation reduced IL-8 expression by 20–30%,
and ZFC3H1 knockdown in HeLa cells inhibited the up-
regulation of IL-8 (Figure 5A). The DNA repair complex
rearrangement occurs following UV irradiation in order to fix
the damaged DNA double helix. Our results suggest that ZFC3H1
may interact with a member of the DNA repair complex through
basic transcription factor components [21,22]. Several stable
HeLa cell lines with shRNAs were tested to examine interactions
between the DNA repair complex and Celastramycin A, and we
revealed that HeLa-shERCC1 cells were insensitive to the
addition of Celastramycin A to the medium (Figure 5B). More-
over, our in vitro experiments showed that Celastramycin A did
not bind to ERCC1, and HeLa-shXPA and HeLa-shXPC cells
showed the Celastramycin A-mediated inhibition of UV-induced
IL-8 expression as control-HeLa cells (data not shown). Immuno-
fluorescence results obtained by a confocal microscope clearly
displayed that ERCC1 and ZFC3H1 localized to cytosolic and
nuclear regions, whereas intense fluorescence spots were observed
in nuclei only (Figure 5C). A merged picture implied the co-
localization of ERCC1 and ZFC3H1; however, our co-immuno-
precipitation experiments using the ERCC1 or ZFC3H1 antibody
did not show the complex formation of these proteins. Thus, an
indirect interaction may be taking place between ZFC3H1 and
ERCC1 in the activated DNA repair complex.
Discussion
ZFC3H1, also designated as CCDC131 (coiled-coil domain
containing protein), or PSRC2 (proline/serine-rich coiled-coil
protein), is a large protein (1989 amino acids), holding a C3H1-
type zinc finger motif in its center, and 5 tetratricopeptide (TRP)
repeats and 6 half-tetratricopeptide (HAT) repeats at the C-
terminal region. Although functional characterizations of this
protein have not yet been reported, RNA binding and protein-
protein interactions were predicted based on the presence of TRPs
and HATs [23,24]. In this respect, we have empirically
demonstrated the possibility that ZFC3H1 participates in keeping
IL-8 mRNA from degradation for the first time. The reporter
assays used in this study revealed that ZFC3H1 regulated IL-8
transcription, and the HeLa cell-UV irradiation assay suggested
indirect interactions between ZFC3H1 and the DNA repair
complex. These interactions may occur in the C-terminal region
and zinc finger motif. Our western blotting and immunofluores-
cence results demonstrated that ZFC3H1 was localized to the
cytosol and nuclei. This localization pattern remained unaltered
with the TNFa stimulation, which indicated that no apparent
nuclear translocation had occurred. Moreover, ZFC3H1 knock-
down caused a slight change in the TNFa-triggered intracellular
phosphorylation cascade. Thus, cytosolic ZFC3H1 may have a
different role from nuclear ZFC3H1.
Our previous studies showed that cytokine signals, including
TNFa, TGF-b, and VEGF, derived from the primary tumor site
affected lung endothelial and epithelial cells to produce a pre-
metastatic phase that facilitated actual tumor cell migration. These
cytokine signals, leading to the lung-specific up-regulation of
S100A8 expression and subsequent enhancement in SAA3
expression, account for lung-specific tumor metastasis [10].
SAA3 functions as an endogenous TLR4/MD-2 ligand to activate
downstream NF-kB signaling [11]. Thus, the S100A8-SAA3-
TLR4 cascade maintains inflammatory reactions in the lung, also
known as homeostatic inflammation; therefore, an anti-inflamma-
tory reagent such as Celastramycin A is expected to mitigate
inflammatory responses in the lung. Although we did not focus on
the detailed molecular mechanisms of Celastramycin A in the
tumor-bearing model mouse system, ZFC3H1 may be a target
molecule for the prevention of tumor metastasis.
In summary, we identified ZFC3H1 as the mammalian target of
Celastramycin A (mTOC). Our study has provided an insight into
this protein for the first time by identifying its functions as a
transcriptional regulator. The results of this study suggest that
mTOC targeting therapeutics could be effective because it is
involved in regulating the expression of inflammatory cytokines.
Supporting Information
Figure S1 Effect of Celastramycin A in LU99 cellular
viability. (A) Correlation between relative cellular viablity of LU
99 cells and Celastramycin A concentration (0–1 mg/ml) Cells
were cultured with various concentrations of Cerastramycin A for
6 h. (B) relative IL-8 expression levels in LU99 cells incubated with
TNFa (5 ng/ml, 90 min) in the presence of various concentrations
of Celastramycin A (0–1 mg/ml). Data were normalized to b-actin
and control LU99 data was set as 1. Three independent
experiments yielded the similar results.
(TIF)
Figure S2 IL-6 production in LU99 cells was attenuated
by Celastramycin A. Control and ZFC3H1 siRNA transfected
LU99 cells were incubated with TNFa (5 ng/ml, 6 h) in the
absence or presence of Celastramycin A (0.1 mg/ml). The culture
media were assayed with an IL-6 ELISA kit (R&D Systems). *P.
0.05. Three independent experiments.
(TIF)
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